Navigation Links
Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
Date:10/7/2010

red Paper session (Abstract #1344O, October 10).(7)

Pfizer continues to investigate approved therapies within its portfolio, including Aromasin® (exemestane tablets).  At the Congress, research findings for the compound will be presented in two key presentations.

- Distant recurrences at median of 5-years among 9,779 postmenopausal women with hormone receptor-positive early breast cancer treated on the TEAM trial of adjuvant endocrine therapy (Abstract #213O, October 11)(8)

- Effects of exemestane or tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis (Abstract #225P, October 10)(9)

Data on the following compounds and investigational agents will also be presented: neratinib (HER2 positive breast, solid tumors),(10),(11) axitinib (renal cell carcinoma or RCC),(12) inotuzumab (non-Hodgkin's lymphoma),(13) and Torisel® (temsirolimus) (RCC, solid tumors).(14),(15)

For more news and information, follow Pfizer Oncology at ESMO through Twitter @pfizer_news (http://twitter.com/pfizer_news).

About Sutent® (sunitinib malate)

Sutent is an oral multi-kinase inhibitor approved for the treatment of advanced RCC and for the treatment of GIST after disease progression on or intolerance to imatinib mesylate.

Sutent works by blocking multiple molecular targets implicated in the growth, proliferation and spread of cancer.  Two important Sutent targets, vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), are expressed by many types of solid tumors and are thought to play a crucial role in angiogenesis, the process by which tumors acquire blood vessels, oxygen and nutrients needed for growth.  Sutent also inhibits other targets important to tumor growth, including KIT, FLT3 and RET.

I
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Boston Scientific Corporation (NYSE: BSX ) is ... May 21-24 in Paris . ... and diversified set of data this year at EuroPCR," ... chief medical officer, Boston Scientific.  "The primary endpoint results ... PROMUS trial, which evaluated our Promus PREMIER ™ ...
(Date:5/16/2013)... 2013  Today, the National Patient Advocate Foundation acknowledges ... of Representatives recently approved a bill that would prohibit ... higher out-of-pocket fees for newer, more expensive oral anti-cancer ... more severe side-effects. However, the bill was amended to ... continue to be a barrier to patients with cancer ...
(Date:5/16/2013)... 2013 OrthoView PSL will allow ... access the widely-used OrthoView digital templating software via the ... to get started. OrthoView, the leading independent ... years, is dedicated to enabling orthopaedic surgeons in hospitals ... when printed film is unavailable. Over 5,000 orthopaedic surgeons ...
Breaking Medicine Technology:Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3OrthoView Announces the U.S. Launch of a New, Subscription-based, Digital Planning and Templating Solution for Individual Orthopaedic Surgeons 2
... , , , GREENSBORO, N.C., Dec. 23 ... for four users who allege kidney damage due to the ... intestines in preparation for a colonoscopy. (Holshouser et al ... actions are against two Morrisville, N.C., pharmaceutical companies, Salix Pharmaceuticals, ...
... , , , , IRVINE, Calif., ... of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion pulse oximetry, ... 28th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis ... p.m. Pacific Time. A live audiocast of the presentation will ...
Cached Medicine Technology:Suits Commenced Against Maker of Prescription Cleansing Drug 2Masimo to Present at the 28th Annual J.P. Morgan Healthcare Conference 2Masimo to Present at the 28th Annual J.P. Morgan Healthcare Conference 3
(Date:5/18/2013)... of coffee is associated with a reduced risk ... disease, Mayo Clinic research shows. The findings were ... conference in Orlando, Fla. , PSC is ... results in inflammation and subsequent fibrosis that can ... and biliary cancer. , "While rare, PSC has ...
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & ... market drivers, restraints, and opportunities in North America, Europe, ... 89 market data tables , ... IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , ... The global healthcare IT market is expected to grow ...
(Date:5/18/2013)... 18, 2013 As metal-on-metal hip ... the country, Bernstein Liebhard LLP notes that a new ... suffer tissue damage before they experience any pain from ... Science Daily will appear in the Journal of Bone ... MRI screens of their hips. The researchers found ...
(Date:5/18/2013)... “Sleep Apnea Diagnostic & Therapeutic Devices Market [Polysomnographs, Respiratory ... Appliances, Nasal EPAP, Neurostimulation] Global End-user Analysis, Competitive Landscape ... market drivers, restraints, and opportunities in North America, Europe, ... 147 market data tables ... 318 pagesand in-depth TOC of “Sleep Apnea Diagnostic ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3
... , FRIDAY, Feb. 18 (HealthDay News) -- Patients with ... radiation treatments have a much lower long-term survival rate than ... the study of patients with squamous cell carcinoma of the ... to smoke were still alive five years after treatment, compared ...
... Scientists at the Children,s Center for Cancer and Blood ... Los Angeles today announced a breakthrough discovery in understanding ... a protein called CD19-ligand (CD19-L) located on the surface ... and destruction of leukemia cells by the immune system. ...
... 18 (HealthDay News) -- Speaking more than one language may ... that bilingual speakers outperform people who speak only one language ... irrelevant information to focus on important information. This means bilingual ... than one project at a time, said Judith Kroll, ...
... bigger role in the American health care system, argued ... conference of the American Association for the Advancement of ... health care costs depend on the policy context in ... Meltzer, Associate Professor of Medicine, in his presentation, "Policies ...
... leading lung cancer screening researchers, doctors and advocates. ... Early Lung Cancer Action Program (I-ELCAP) Screening Conferences. ... International Early Lung Cancer Action Program (I-ELCAP) and ... International Lung Cancer Consortium (ILCCO). This meeting ...
... (Feb 18, 2011) James C. Wittig, M.D., chief ... the John Theurer Cancer Center at Hackensack University Medical ... approaches to orthopedic oncology at the upcoming American Academy ... inventing some of the most-used best practices in limb-sparing ...
Cached Medicine News:Health News:Smoking During Head & Neck Cancer Therapy Tied to Poor Outcome 2Health News:Scientists bioengineer a protein to fight leukemia 2Health News:Cost-effectiveness research needs to be considered in developing new medical technology 2Health News:World's largest lung cancer screening conference to address benefits of CT scans 2Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 2Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 3Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 4Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 5Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 6Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 7
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... The AccuDrain System is a panel mounted system ... many critical needs of the heath care professional ... drainage system available with a dual action lever ... quickly attached to an IV pole. Similarly, ...
Medicine Products: